基于PET/CT与临床实验室参数的诊断模型鉴别不明原因发热中淋巴瘤与良性淋巴结病
本研究回顾性分析203例不明原因发热(FUO)伴淋巴结增大患者(淋巴瘤114例、良性淋巴结病89例),基于临床、实验室及PET/CT代谢参数构建联合诊断模型。联合模型纳入皮疹、PCT、SAA、SUVmean和TMTV,AUC达0.965,显著优于仅基于临床(AUC=0.790)、实验室(AUC=0.866)或PET(AUC=0.845)的模型(均P<0.001)。
要点
- 皮疹、PCT、SAA、SUVmean、TMTV为FUO中鉴别淋巴瘤与良性淋巴结病的独立预测因子。
- 联合临床、实验室与PET参数的模型AUC为0.965,优于任一单一维度模型。
- 基于联合模型构建的列线图可用于个体化风险预测。
核心结论
- 皮疹、PCT、SAA、SUVmean和TMTV是鉴别FUO中淋巴瘤与良性淋巴结病的独立预测因子。
- 整合临床、实验室和PET参数的联合模型显著提高了诊断准确性,AUC为0.965。
研究设计与样本
- 回顾性分析接受PET/CT检查的FUO患者,淋巴结纳入标准为轴位CT短轴直径≥1 cm或代谢活性高于纵隔血池。
- 在LIFEx中以40% SUVmax阈值手动勾画感兴趣区,共纳入203例患者(淋巴瘤114例,良性淋巴结病89例)。
- 采用logistic回归分析筛选独立预测因子,并构建联合诊断模型与列线图。
主要发现
- 临床因素中高热、关节痛和皮疹为独立预测因子;实验室指标中ALB、PCT和SAA为独立预测因子;PET参数中SUVmean、TMTV和TLG为独立预测因子。
- 联合模型纳入皮疹、PCT、SAA、SUVmean和TMTV,AUC为0.965。
- 仅基于临床变量的模型AUC为0.790,仅基于实验室变量的模型AUC为0.866,仅基于PET变量的模型AUC为0.845,联合模型均显著优于上述模型(均P<0.001)。
关键数值与推荐
- 联合模型AUC=0.965,显著高于临床模型(AUC=0.790)、实验室模型(AUC=0.866)和PET模型(AUC=0.845),均P<0.001。
- 淋巴结纳入标准:轴位CT短轴直径≥1 cm或代谢活性超过纵隔血池。
- 感兴趣区勾画采用40% SUVmax阈值。
临床怎么用
- 对于FUO伴淋巴结增大患者,可结合皮疹、PCT、SAA、SUVmean和TMTV构建的列线图进行个体化风险预测,辅助鉴别淋巴瘤与良性淋巴结病。
- PET/CT代谢参数(SUVmean、TMTV)应与临床特征和实验室指标联合解读,而非单独依赖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fever of unknown origin (FUO) remains a complex diagnostic challenge, with infection, malignancy, and inflammatory diseases as the leading causes. A substantial proportion of FUO patients present with lymphadenopathy, among which lymphoma and benign lymph node disorders are the most critical differential diagnoses due to their markedly different management and prognosis. Although 18F-FDG PET/CT plays an indispensable role in lymphoma detection, significant metabolic overlap between malignant and benign lymphadenopathy limits its standalone diagnostic accuracy in FUO. Therefore, integrating PET/CT metabolic parameters with clinical features and laboratory markers may improve the differentiation between lymphoma and benign lymphadenopathy, facilitating timely and accurate diagnosis in FUO patients. RESULTS: This study retrospectively analyzed patients with FUO who underwent PET/CT. Lymph nodes were included if their short-axis diameter was ≥ 1 cm on axial CT or if metabolic activity exceeded that of the mediastinal blood pool. Volumes of interest were manually delineated in LIFEx using a 40% SUVmax threshold. Among 203 patients (114 with lymphoma and 89 with benign lymphadenopathy), logistic regression analyses identified independent predictors across three domains: hyperpyrexia, joint pain, and rash among clinical factors; albumin (ALB), procalcitonin (PCT), and serum amyloid A (SAA) among laboratory indicators; and SUVmean, total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG) among PET parameters. A combined model incorporating rash, PCT, SAA, SUVmean, and TMTV achieved superior diagnostic performance, with an area under the ROC curve (AUC) of 0.965, significantly outperforming models based solely on clinical (AUC = 0.790), laboratory (AUC = 0.866), or PET (AUC = 0.845) variables (all P < 0.001). A nomogram was subsequently developed for individualized risk prediction. CONCLUSIONS: Rash, PCT, SAA, SUVmean, and TMTV were independent predictors distinguishing lymphoma from benign lymphadenopathy in FUO. Integrating clinical, laboratory, and PET parameters markedly improved diagnostic accuracy.
引用
- Zhang X, Hu Y, Di Y, et al. Distinguishing lymphoma from benign lymphadenopathy in fever of unknown origin using a diagnostic model based on PET/CT and clinical-laboratory parameters. EJNMMI Res. 2026. PMID: 42154405. doi:10.1186/s13550-026-01450-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。